Enteric coated pharmaceutical composition and method of manufacturing

Abstract

A high drug load enteric coated pharmaceutical composition is provided which includes a core comprised of a medicament which is sensitive to a low pH environment of less than 3, such as ddl, which composition is preferably in the form of beadlets having an enteric coating formed of methacrylic acid copolymer, plasticizer and an additional coat comprising an anti-adherent. The so-called beadlets have excellent resistance to disintegration at pH less than 3 but have excellent drug release properties at pH greater than 4.5. A novel method of making said pharmaceutical composition is also disclosed.

We claim:  
     
         1 . An enteric coated pharmaceutical composition comprising a core in the form of a beadlet, pellet, granule or particle and an enteric coating for said core, said core comprising an acid labile medicament in an amount within the range from about 50 to about 100% by weight of said composition, a binder in an amount within the range from about 0 to about 10% by weight of said composition, a disintegrant in an amount within the range of from about 0 to about 10% by weight of said composition, and said enteric coating comprising a methacrylic acid copolymer, and a plasticizer said enteric coating imparting protection to said core so that said core is afforded protection in a low pH environment of 3 or less while capable of releasing medicament at a pH of 4.5 or higher, said pharmaceutical composition also comprising an anti-adherent in an amount within the range of from about 0.1 to about 4.0% by weight.  
     
     
         2 . The pharmaceutical composition according to    claim 1   , wherein said core is in the form of a beadlet or pellet.  
     
     
         3 . The pharmaceutical composition according to    claim 2   , wherein said core is in the form of a beadlet.  
     
     
         4 . The pharmaceutical composition according to    claim 1   , wherein said enteric coating is present in a weight ratio to the core of within the range of from about 0.05:1 to about 0.6:1.  
     
     
         5 . The pharmaceutical composition according to    claim 1   , wherein said enteric coating includes the methacrylic acid copolymer in an amount within the range of from about 5 to about 30% by weight, and said plasticizer in an amount within the range from about 0.5 to about 6% by weight, all of the above % being based on the solids content of said enteric coating.  
     
     
         6 . The pharmaceutical composition according to    claim 5   , wherein said methacrylic acid copolymer is Eudragit L-30-D 55.  
     
     
         7 . The pharmaceutical composition according to    claim 5   , wherein said plasticizer is diethyl phthalate, triethyl citrate, triacetin, tributyl sebecate, or polyethylene glycol.  
     
     
         8 . The pharmaceutical composition according to    claim 7   , wherein said plasticizer is diethyl phthalate.  
     
     
         9 . The pharmaceutical composition according to    claim 8   , wherein said enteric coating includes methacrylic acid copolymer and diethyl phthalate.  
     
     
         10 . The pharmaceutical composition according to    claim 1   , wherein said anti adherent is a hydrophobic material.  
     
     
         11 . The pharmaceutical composition according to    claim 10   , wherein the anti adherent is talc, magnesium stearate or fumed silica.  
     
     
         12 . The pharmaceutical composition according to    claim 11   , wherein the anti-adherent is talc.  
     
     
         13 . The pharmaceutical composition according to    claim 1   , wherein said anti-adherent is present in an amount within the range from about 0.1% to about 4.0% by weight, all of the above % being based on the solids content of said enteric coating.  
     
     
         14 . The pharmaceutical composition according to    claim 1   , wherein the pH of said acidic enteric coating is adjusted using alkalizing agents to improve stability between said acid labile medicament in said core and said acidic enteric coating.  
     
     
         15 . The pharmaceutical composition according to    claim 14   , wherein adjustment of the pH of said acidic enteric coating eliminates incompatibility between said acid labile medicament in said core and said acidic enteric coating.  
     
     
         16 . The pharmaceutical composition according to    claim 15   , wherein adjustment of said pH of said acidic enteric coating eliminates the need for a protective subcoat between said acid labile medicament in said core and said acidic enteric coating.  
     
     
         17 . The pharmaceutical composition according to    claim 16   , wherein elimination of said protective subcoat permits quicker release of said acid labile medicament in said core.  
     
     
         18 . The pharmaceutical composition according to    claim 1   , wherein said medicament is present in an amount within the range of from about 50 to about 100% of the core composition when said core composition is uncoated.  
     
     
         19 . The pharmaceutical composition according to    claim 1   , wherein said medicament is ddl.  
     
     
         20 . The pharmaceutical composition according to    claim 1   , wherein said medicament is pravastatin, erythromycin, digoxin, pancreatin, ddA or ddC.  
     
     
         21 . The pharmaceutical composition according to    claim 1   , wherein said core includes disintegrant present in an amount within the range of from about 0 to about 10.0% by weight.  
     
     
         22 . The pharmaceutical composition according to    claim 1   , wherein said disintegrant is sodium starch glycolate, croscarmellose sodium, corn starch, or cross linked polyvinylpyrrolidone.  
     
     
         23 . The pharmaceutical composition according to    claim 22   , wherein said disintegrant is sodium starch glycolate.  
     
     
         24 . The pharmaceutical composition according to    claim 1   , wherein said core includes a binder present in an amount within the range of from 0 to about 10% by weight.  
     
     
         25 . The pharmaceutical composition according to    claim 24   , wherein said binder is sodium carboxymethylcellulose, Avicel™ PH101, Avicel™ RC 591. Avicel™ CL-611, Methocel™ E-5, Starch 1500, Hydroxypropyl Methylcellulose, Polyvinylpyrrolidone, Potassium Alginate or Sodium Alginate.  
     
     
         26 . The pharmaceutical composition according to    claim 24   , wherein said binder is sodium carboxymethylcellulose.  
     
     
         27 . The pharmaceutical composition according to    claim 24   , wherein said binder is alkaline in nature.  
     
     
         28 . The pharmaceutical composition according to    claim 27   , wherein said said core comprising said acid labile medicament is made more stable by the inclusion of said alkaline binder.  
     
     
         29 . The pharmaceutical composition according to    claim 1   , wherein said core comprising said acid labile medicament is made more stable by the inclusion of an alkaline ingredient such as magnesium oxide.  
     
     
         30 . The pharmaceutical composition according to    claim 1   , having the following composition:  
                                           Material   % (range)                   CORE             Drug (didanosine)     50-100.0         NaCMC     0-10.0         Na Starch Glycolate     0-10.0         COATING         Eudragit L-30-D 55    5.0-30.0         Diethyl Phthalate   0.5-6.0                   ANTI-ADHERENT COAT                       Talc   0.1-4.0                                                               
     
     
         31 . An enteric coated ddl comprising a core in the form of a beadlet or pellet which includes ddl in an amount within the range of from about 50 to about 100% by weight of said core, and an enteric coating which includes a methacrylic acid copolymer.  
     
     
         32 . ddl as defined to    claim 31   , in the form of beadlets.  
     
     
         33 . ddl as defined in    claim 32   , wherein the enteric coating includes a methacrylic acid copolymer and a plasticizer.  
     
     
         34 . ddl as defined in    claim 33   , further comprising an anti-adherent.  
     
     
         35 . A process for the preparation of an enteric-coated pharmaceutical composition comprising the steps of: 
 (a) preparing a dry blend comprising a medicament, a binder and a disintegrant, and setting a portion of said dry blend aside;    (b) forming a wet mass from the remainder of said dry blend not set aside in step (a);    (c) extruding said wet mass to form an extrudate and spheronizing said extrudate into high-potency beadlets by dusting said wet mass extrudate with said portion of said dry blend set aside in step (a);    (d) coating said beadlets with an enteric coating polymer and plasticizer in an aqueous media; and    (e) blending said coated beadlets with an anti-adherent.    
     
     
         36 . The process according to    claim 35   , further comprising the step of separating said spheronized high potency beadlets formed in step (c) using a #10 and a #18 size mesh screen to form 10/18 mesh product fraction sized beadlets prior to said coating step (d).  
     
     
         37 . The process according to    claim 35   , wherein said medicament is an acid labile drug.  
     
     
         38 . The process according to    claim 37   , wherein said acid labile drug is selected from the group consisting of ddl, pravastatin, erythromycin, digoxin, pancreatin, ddA or ddC.  
     
     
         39 . The process according to    claim 38   , wherein said medicament is ddl.  
     
     
         40 . The process according to    claim 35   , wherein said binder is sodium carboxymethylcellulose.  
     
     
         41 . The process according to    claim 35   , wherein said disintegrant is sodium starch glycolate.  
     
     
         42 . The process according to    claim 35   , wherein the wet mass is formed by the addition of a granulation solvent.  
     
     
         43 . The process according to    claim 42   , wherein said granulation solvent is water.  
     
     
         44 . The process according to    claim 35   , wherein said plasticizer is diethyl phthalate.  
     
     
         45 . The process according to    claim 44   , wherein said enteric coating includes methacrylic acid copolymer and diethyl phthalate.  
     
     
         46 . The process according to    claim 45   , wherein said methacrylic acid polymer is Eudragit L-30-D 55.  
     
     
         47 . The process according to    claim 35   , wherein said anti-adherent is talc.  
     
     
         48 . The process according to    claim 35   , further providing the step of filling said coated beadlets prepared in (e) into a dissolvable capsule.